Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News

Tylenol Use in Pregnancy May Be Linked With Uterus, Ovary Changes in Daughters

Female reproductive organ development may be impacted by a mother's use during pregnancy of Tylenol or its generic versions, according to researchers who emphasize that...

Ionis Pharma Prices First FDA-approved Treatment for Alexander Disease At $285,000 Per Dose

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

New Migraine Prevention Guidelines Released

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis Pauses Trials Of Experimental Cell Therapy After Three Deaths

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

New Stroke Rehab Guideline Calls for Earlier, Broader Care

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.

Borderline Personality: Evidence Has Evolved. Care Hasn’t

A quiet revolution in borderline personality disorder has exposed a disconnect: Treatment works, recovery is possible, yet outdated assumptions continue to shape clinical care.

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

Latest News

Female reproductive organ development may be impacted by a mother's use during pregnancy of Tylenol or its generic versions, according to researchers who emphasize that...

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.

A quiet revolution in borderline personality disorder has exposed a disconnect: Treatment works, recovery is possible, yet outdated assumptions continue to shape clinical care.

News All Time

Dravet Syndrome Clinical Pearls: Uncovering Disease Impact and Partnering With Patients and Caregivers to Individualize Treatment Plans

Dravet Syndrome Clinical Pearls: Uncovering Disease Impact and Partnering With Patients and Caregivers to Individualize Treatment Plans

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Superagers' Exceptional Memory Can't Be Explained by Genes Alone, Study Finds

Inherited Alzheimer's risk didn't differ between superagers and cognitively average older adults

Diarrhea Bug Outbreak Hits 4 More States; Fauci to Testify; Doc Dies in House Fire

Health news and commentary gathered by MedPage Today staff

Hold Off on JAK Inhibitors in Rheumatoid Arthritis Until After Shingles Vax?

Good things come to those who wait -- and to those who don't wait

FDA Approves Tylenol With Naproxen Combination

First OTC fixed-dose combination product to pair acetaminophen with naproxen sodium

FDA Panel Finds a Peptide It Doesn't Like

Over 2-day meeting, six of seven peptides are recommended for adding to bulk compounding list

Brain Worm Culprit in Woman's Hallucinations, Incoherent Speech

MRI uncovers neurocysticercosis in a 52-year-old woman

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

FDA Scientists Raise Questions About Duchenne Drug

Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Feds Delay Autism Meeting; Wildfire Smoke and Migraine; Mortality and MS

News and commentary from the world of neurology and neuroscience

Sugar Rationing in Early Life Linked to Lower Dementia Risk Decades Later

Long-term study looks at what happened when sugar was scarce

FDA Committee Votes Down Duchenne Drug

Agency staff and drug developer disagree on endpoints

Alzheimer's Paper Retracted; MS Before Epstein-Barr Infection; Brain Aging Map

News and commentary from the world of neurology and neuroscience

Fauci Successor Imminent; CDC Expands Outbreak List; Pesticides Linked to ALS

Health news and commentary gathered by MedPage Today staff

Recommended News For You

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care

Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

In women with extremely dense breasts, elevated MRI enhancement can help identify cancer risk.

Most NMIBC Recurrences Seen in BCG-Exposed Patients

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

Recommended Articles For You

Patient Management After Personalized Surgical Oncology Reconstruction 

Advancements in Breast Cancer Treatment: From Chemotherapy to Immunotherapy 

Understanding Lymphedema: Symptoms, Causes, and Treatment  

RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

I Watched My Friend Choose Death. Physician-Assisted Suicide Needs More Guardrails.

2.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

3.

Prostate Cancer Treatment Associated With Long-Term Complications

4.

Investigating the Relationship Between GERD and Anxiety/Depression.

5.

When Should Immunocompromised Individuals Receive a COVID Booster?

1.

The Ins and Outs of Glossectomy: What You Need to Know 

2.

Exploring the Unknown: Unveiling the Mysteries of GIST Tumors

3.

Comprehensive Standards in Oncology for Modern Medicine

4.

Uncovering the Mysteries of Breast Cancer: The Journey to a Cure

5.

Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

4.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment

5.

Navigating the Complexities of Ph Negative ALL - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot